Global Antibiotic Development Fund (GADF): Separating Antibiotic Economics from Market Incentives
Description
Establish a Global Antibiotic Development Fund (GADF) capitalized at $15B that operates as a 'push + pull' mechanism decoupled from traditional pharmaceutical markets.
Push component: Fund R&D through competitive grants to academic labs, biotech startups, and pharmaceutical companies — rewarding breakthroughs in new molecular entities and new mechanisms of action, not profit potential.
Pull component: Guaranteed purchase commitments for antibiotics meeting WHO priority criteria, with tiered pricing: drugs listed on WHO Essential Medicines List are purchased at cost ($10-50 per course) for distribution in low-income countries; drugs for high-income country hospital use are purchased at premium prices ($500-2,000 per course).
Critically, the GADF acquires global rights to the drug once it reaches market, preventing monopoly pricing while ensuring the developer recovers their investment. Distribution: WHO coordinates generic manufacturing and supply chain to ensure universal access.
Governance: Independent scientific committee determines which pathogens and resistance profiles are 'high priority,' preventing the GADF from being captured by commercial interests or non-urgent requests.
Implementation Pathway
Phase 1 (2025–2027)
- • GADF charter negotiated via WHO Assembly
- • Initial capitalization of $5B from G20 pledges
- • First 10 grant rounds deployed
Phase 2 (2027–2032)
- • GADF fully capitalized at $15B
- • 20+ new antibiotics in clinical development
- • 3–5 new drugs approved and distributed to 50+ countries
Phase 3 (2032+)
- • GADF becomes permanent global mechanism
- • Antibiotic development pipeline stabilized
- • Resistance containment strategies operationalized in all regions
Required Resources
Impact Analysis
Overall Net Impact
Combined analysis across all timeframes
Short-term
0-2 years
No benefits identified
No harms identified
Mid-term
3-10 years
No benefits identified
No harms identified
Long-term
10+ years
No benefits identified
No harms identified